Hematology

The addition of navitoclax was associated with durable response and potential disease modification.

Methemoglobinemia is a blood disorder that affects proper release of oxygen around the body.

Lisocabtagene maraleucel chimeric antigen receptor T-cell therapy significantly enhances treatment of relapsed/refractory B-cell malignancies, offering high response rates and durable remissions.

This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.

Data show that a child’s insurance status is independently associated with mortality after hematopoietic cell transplantation.

Belantamab mafodotin demonstrated benefits in overall survival in the phase 3 DREAMM-7 trial.

Rusfertide may sustain hematocrit levels in patients with polycythemia vera.

There were 2 main types of switches, including switching to rituximab subcutaneous and switching among different intravenous rituximab treatments.

The indication is for adult and pediatric patients 1 year and older with a lysine methyltransferase 2A gene translocation.

The tablets become the first and only nilotinib with no mealtime restrictions indicated for this population.

According to the study, 20% of patients with myeloproliferative neoplasms progress to blast phase.

LBL-034 could be best in class in treating individuals with multiple myeloma.

If accepted, daratumumab would be the first approved treatment for smoldering multiple myeloma.

The regulatory approval corresponds with positive safety and efficacy data from the FELIX trial.

Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.

Increased bone marrow adiposity is associated with progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

Pegfilgrastim (Neulasta; Amgen) treats neutropenia that is caused by cancer medications and helps the bone marrow to create new white blood cells.

ELA026 is a first in class antibody therapy targeting signal regulatory proteins.

Approximately 15% of patients with polycythemia vera will progress to myelofibrosis.

In the results, 31% of patients maintained undetectable measurable residual disease 4 years after treatment.

A patient with BPDCN finds her champion.

The accelerated approval comes after 48-week major molecular response rate data.

The new indications include pediatric individuals with acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.

The study was conducted on a small subgroup of Japanese patients with myelofibrosis.

This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.

Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.

This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.

Courtney VanHouzen, PharmD shares insights about the community bispecific program at Munson Healthcare.

The real-world study results of ciltacabtagene autoleucel are comparable to data from the CARTITUDE-1 trial, emphasizing its efficacy and safety.